Agree with the article in ACHN potencial, and adding value to BMY or ABBV un getting better combos ( cheaper and por lower weeks of treatments) On the other side, I believe RGLS drug will never reach the market. I dont see the subcutaneus injection if by the time there will be a crowded market with oral drugs
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.